|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein C3 (APOC3), which is an important regulator of human lipid metabolism, is associated with multiple vascular mechanisms in atherosclerosis and proinflammatory responses.
|
31004933 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, treating both mouse models with an APOC3 antisense oligonucleotide lowered both plasma APOC3 and TRLs, and prevented atherosclerosis.
|
31449060 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of High-Density Lipoprotein Particles and High-Density Lipoprotein Apolipoprotein C-III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi-Ethnic Study of Atherosclerosis.
|
31818211 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our observations demonstrate that relative insulin deficiency increases APOC3 and that this results in elevated levels of TRLs and accelerated atherosclerosis in a mouse model of T1DM.
|
31295146 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.
|
30949716 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A high level of APOC3 expression is an independent risk factor for some lipid metabolism-related diseases, such as cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and atherosclerosis (AS).
|
29555504 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III and Subclinical Atherosclerosis Measures: MESA (The Multi-Ethnic Study of Atherosclerosis).
|
29540426 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated how the presence of apoC-III affects the association between HDL and early stages of atherosclerosis measured as carotid intima-media thickness (cIMT).
|
29351856 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis.
|
28441154 |
2017 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relationship between the S2 allele of the SstI polymorphism and plasma apoCIII or TG and their roles in atherosclerosis are also unknown.
|
29162127 |
2017 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence indicates that apolipoprotein C-III is a multifaceted protein which not only regulates triglyceride metabolism, but also participates in the atherosclerotic lesion formation and several other pathological processes involved in atherosclerosis.
|
27770802 |
2016 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the association of LpPLA2 activity and ApoC3 LOF mutations and incident cardiovascular disease (CVD) (defined as coronary heart disease [CHD] plus ischemic stroke) and all-cause mortality in the biracial longitudinal Atherosclerosis Risk In Communities (ARIC) study.
|
26117401 |
2015 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, AR ameliorated atherosclerosis via the regulation of hepatic lipid metabolism, and AR also contributed to the activation of PPAR-alpha, APOA1, APOA2 and APOC3.
|
25979856 |
2015 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ApoC-III is a proatherogenic protein associated with elevated triglycerides; its deficiency is associated with reduced atherosclerosis.
|
22236405 |
2012 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
|
19074352 |
2008 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A synergistic interaction between the apolipoprotein C-III and the LDL receptor defects produced large quantities of VLDL and LDL and enhanced the development of atherosclerosis.
|
8994037 |
1997 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Global severity of atherosclerosis at the first angiography was weakly associated with genotypes of the apoCIII-C/T1100 polymorphism, presence of the T1100 allele being associated with 53% lower median score (1.6 vs 0.75; p = 0.09).(ABSTRACT TRUNCATED AT 400 WORDS)
|
7834891 |
1994 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A DNA polymorphism of the apolipoprotein C-III gene in extracoronary atherosclerosis.
|
3345637 |
1988 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that absence of transcripts with correct apoAI and apoCIII mRNA sequences causes apoAI and apoCIII deficiency in the plasma of these patients and suggest that these apolipoproteins are involved in cholesterol homeostasis and protection against premature atherosclerosis.
|
3118360 |
1987 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have recently reported that the human apolipoprotein A-I (apoA-I) and apolipoprotein C-III (apoC-III) genes are physically linked and that the presence of a DNA insertion in the apoA-I gene is correlated with apoA-I-apoC-III deficiency in patients with premature atherosclerosis.
|
2989400 |
1985 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA polymorphisms in the apolipoprotein C-III and insulin genes and atherosclerosis.
|
3911967 |
1985 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have recently isolated and characterized the human apo A-I gene and have shown that apo A-I and apolipoprotein C-III (apo C-III) genes are physically linked and that a polymorphism (of unknown frequency in the general population) of the apo A-I gene is inherited as a mendelian trait linked to premature atherosclerosis in an affected family (not the same polymorphism as has previously been reported to be associated with hypertriglyceridaemia).
|
6314145 |
1983 |